Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Sushil Pant

Dr Sushil Pant

Frozen Shoulder – A Practical Guide to Assessment and Management

Dr Robert Hungerford

Dr Robert Hungerford

Implementing the Four Pillars of Heart Failure Management in GP

Prof Robert Norman

Prof Robert Norman

PCOS Update

Dr Clare Tiedeman

Dr Clare Tiedeman

Biologics in COPD – 20% of Your Patients Could Benefit

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022